The U.S. Food and Drug Administration (FDA) has released new guidelines to help companies that make advanced treatments called cellular and gene therapies (CGTs) ensure these products work as intended. These guidelines replace older recommendations from 2011 and focus on maintaining the strength and effectiveness of these treatments throughout their entire lifecycle, from early development to after they are sold to patients. The updated guidance, called *Potency Assurance for Cellular and Gene Therapy Products*, explains how manufacturers should control the quality of raw materials, perform tests during production, and use lab methods to confirm that each batch of therapy is biologically active and matches the intended health benefits. The rules also address specific challenges in making these therapies, such as products that spoil quickly, therapies that use viruses to deliver genes, and treatments made specifically for individual patients. The FDA advises companies to consider potency—the ability of the therapy to work as intended—at every step, from early research and clinical trials to final approval and even after the therapy is available to patients. This approach aims to speed up access to safe and effective treatments for people who have few or no other options. Karim Mikhail, Director of the FDA’s Center for Biologics Evaluation and Research, stressed that patients need to trust that the therapies they receive will work properly and that innovation must always go hand-in-hand with the highest standards of safety and quality.